Caeregen Therapeutics Announces FDA Rare Pediatric Disease Designation for Noregen™ in the Treatment Of Familial Exudative Vitreoretinopathy (FEVR)
Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment of Familial Exudative Vitreoretinopathy (FEVR) as a drug for “rare pediatric disease*”.
United States Kimberlya Drenser Walter Capone Walterm Capone European Commission Ec Medicines Agency Drug Administration
Source: biospace.com